-
1 Comment
CymaBay Therapeutics, Inc is currently in a long term downtrend where the price is trading 26.0% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
CymaBay Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 46.4% to $-16M since the same quarter in the previous year.
Finally, its free cash flow grew by 47.4% to $-15M since the same quarter in the previous year.
Based on the above factors, CymaBay Therapeutics, Inc gets an overall score of 3/5.
| Industry | Biotechnology |
|---|---|
| Sector | Healthcare |
| ISIN | US23257D1037 |
| CurrencyCode | EUR |
| Exchange | F |
| Beta | 0.29 |
|---|---|
| Dividend Yield | 0.0% |
| Target Price | 10.8 |
| PE Ratio | None |
| Market Cap | 804M |
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for C0I.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
